GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903829210 | Thyroid | ATC | positive regulation of cellular protein localization | 167/6293 | 276/18723 | 3.32e-20 | 5.38e-18 | 167 |
GO:007265928 | Thyroid | ATC | protein localization to plasma membrane | 161/6293 | 284/18723 | 8.45e-16 | 6.52e-14 | 161 |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:199077826 | Thyroid | ATC | protein localization to cell periphery | 181/6293 | 333/18723 | 3.72e-15 | 2.56e-13 | 181 |
GO:0032970210 | Thyroid | ATC | regulation of actin filament-based process | 208/6293 | 397/18723 | 5.82e-15 | 3.80e-13 | 208 |
GO:0032956210 | Thyroid | ATC | regulation of actin cytoskeleton organization | 190/6293 | 358/18723 | 1.73e-14 | 1.01e-12 | 190 |
GO:003134623 | Thyroid | ATC | positive regulation of cell projection organization | 186/6293 | 353/18723 | 7.99e-14 | 4.23e-12 | 186 |
GO:001081029 | Thyroid | ATC | regulation of cell-substrate adhesion | 128/6293 | 221/18723 | 8.74e-14 | 4.57e-12 | 128 |
GO:015011527 | Thyroid | ATC | cell-substrate junction organization | 70/6293 | 101/18723 | 2.29e-13 | 1.09e-11 | 70 |
GO:0007044111 | Thyroid | ATC | cell-substrate junction assembly | 65/6293 | 95/18723 | 4.11e-12 | 1.62e-10 | 65 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:015011627 | Thyroid | ATC | regulation of cell-substrate junction organization | 51/6293 | 71/18723 | 5.01e-11 | 1.63e-09 | 51 |
GO:0048041110 | Thyroid | ATC | focal adhesion assembly | 59/6293 | 87/18723 | 7.05e-11 | 2.23e-09 | 59 |
GO:0001952110 | Thyroid | ATC | regulation of cell-matrix adhesion | 78/6293 | 128/18723 | 2.09e-10 | 6.15e-09 | 78 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
GO:005189325 | Thyroid | ATC | regulation of focal adhesion assembly | 47/6293 | 66/18723 | 4.64e-10 | 1.25e-08 | 47 |
GO:009010925 | Thyroid | ATC | regulation of cell-substrate junction assembly | 47/6293 | 66/18723 | 4.64e-10 | 1.25e-08 | 47 |
GO:006156423 | Thyroid | ATC | axon development | 220/6293 | 467/18723 | 6.85e-10 | 1.80e-08 | 220 |
GO:0030100111 | Thyroid | ATC | regulation of endocytosis | 113/6293 | 211/18723 | 1.71e-09 | 4.22e-08 | 113 |
GO:007050723 | Thyroid | ATC | regulation of microtubule cytoskeleton organization | 85/6293 | 148/18723 | 2.17e-09 | 5.21e-08 | 85 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHA3 | SNV | Missense_Mutation | | c.960N>T | p.Met320Ile | p.M320I | P29320 | protein_coding | tolerated(0.13) | benign(0.014) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
EPHA3 | SNV | Missense_Mutation | novel | c.1535N>A | p.Arg512Gln | p.R512Q | P29320 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA3 | SNV | Missense_Mutation | novel | c.649N>A | p.Pro217Thr | p.P217T | P29320 | protein_coding | tolerated(1) | probably_damaging(0.991) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
EPHA3 | SNV | Missense_Mutation | | c.285N>G | p.Ile95Met | p.I95M | P29320 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA3 | SNV | Missense_Mutation | | c.2147N>T | p.Ala716Val | p.A716V | P29320 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA3 | SNV | Missense_Mutation | | c.947A>T | p.Asp316Val | p.D316V | P29320 | protein_coding | deleterious(0) | possibly_damaging(0.598) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
EPHA3 | SNV | Missense_Mutation | | c.1457N>C | p.Ile486Thr | p.I486T | P29320 | protein_coding | tolerated(1) | probably_damaging(0.994) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA3 | SNV | Missense_Mutation | | c.2712N>G | p.Asp904Glu | p.D904E | P29320 | protein_coding | tolerated(0.44) | possibly_damaging(0.857) | TCGA-E9-A1R2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
EPHA3 | insertion | Frame_Shift_Ins | novel | c.1227_1228insTTTTTACATTTCTATTCCCTCTTGCTGTATGTTGGTCATAG | p.Asp410PhefsTer23 | p.D410Ffs*23 | P29320 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
EPHA3 | deletion | Frame_Shift_Del | | c.2115_2122delTTCCTTGG | p.Ser706Ter | p.S706* | P29320 | protein_coding | | | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 249565850 | | |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antibody | 310264706 | | |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Ifabotuzumab | | |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | KB004 | | |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | KB-004 | KB-004 | |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 249565821 | | |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 363894214 | SITRAVATINIB | |
2042 | EPHA3 | ENZYME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | CHEMBL24828 | VANDETANIB | |